1761-1770 of 2650 results
New Aim Pty Ltd v Leung: assisting expert witnesses – how much is too much?
In New Aim Pty Ltd v Leung the Federal Court of Australia rejected an expert report and oral evidence from a purportedly independent expert witness, on the basis that the solicitors who retained the expert had written her report. The case is a timely reminder of best (and worst) practices in the engagement of independent expert witnesses and the importance of preserving an expert's independence. ...
Allens advises Octopus Australia on launch of renewable energy funds
OASIS and OREO will co-invest into an Australian renewable energy portfolio, across wind, solar and storage projects. The investment platform will finance the entire renewable energy life cycle fro ...
In Touch: Energy industry granted interim authorisation and other developments
The latest in competition and consumer law. ...
Allens tops mid-year M&A league tables
Allens ranked first for deal value in the announced Australasian M&A league tables in both the Mergermarket and Bloomberg rankings, and second in the Refinitiv rankings. The firm also topped ...
Employment and Safety: Key employment changes from 1 July 2022 and other developments
The latest issues, decisions and proposed changes impacting business and workplace risk ...
More detail on the ESB's proposed capacity mechanism
With so much recent commentary on the perks and pitfalls of a capacity mechanism, this Insight takes a step back and unpacks what we know about the proposal and what it will look like for both generators and retailers in the future. ...
Allens advises Igneo Infrastructure Partners on the acquisition of Elliott Green Power Australia
Under the deal, Atmos Renewables has acquired EGP's portfolio of the Childers, Susan River and Nevertire solar farms with a combined capacity of 302 MW, generating approximately 500GWh of energy ...
Allens advises Liontown on world-class Kathleen Valley Lithium Project
With the execution of the third offtake agreement and funding facility with Ford, the Liontown Board made the Final Investment Decision to proceed to develop the project. 'This is a significant ...
The mRNA rush
There is great potential for mRNA technology to revolutionise future vaccines, and treatment of various conditions such as rare genetic disorders, other infectious diseases and even cancer. The enthusiasm for the technology – or the 'mRNA rush' – is reflected by a spike in patent filings over the past five years, and the growing patent portfolios of key mRNA pioneers and market players. ...